Citations

Clear

2228 citation(s) found for "Le, Anne".

Current Knowledge and Gaps in Geriatric Rehabilitation among Physical and Rehabilitation Medicine specialists
Capodaglio, Paolo , Antoniadou, Eleftheria , Oh‐Park, Mooyeon , Frontera, Walter R, Terzic, Carmen M., Ambrose, Anne Felicia , Pola, Marta Supervía, Kutsal, Yesim Gokce, Strasser, Dale C., Bean, Jonathan F. , Seijas, Vanessa , Lim, Jae-Young, Frontera, Walter R. , Han, Der‐Sheng , Gimigliano, Francesca , Kutsal, Yeşim Gökçe, Nguyen, Vu Q. C.

Mayo Clinic

Annals of Geriatric Medicine and Research | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.4235/agmr.26.0149 | PMID 42581575 Get It

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project
Miola, Alessandro , Croatto, Giovanni , Carvalho, Andre F, Berk, Michael, Nikolitch, Katerina , Saraf, Gayatri , Yatham, Lakshmi N, Frye, Mark A, Singh, Balwinder, Krinitski, Damir , Højlund, Mikkel , Serretti, Alessandro , Gomes, Fabiano A, Hansen, Anne Sofie , Nielsen, Rene Ernst, Manchia, Mirko, Vazquez, Gustavo, Siafis, Spyridon, Leucht, Stefan, Yıldız, Ayşegül, Delorme, Richard, Schaffer, Ayal , Stubbs, Brendon , Rubaiyat, Ruby , Vieta, Eduard, Correll, Christoph U, Moher, David, Cortese, Samuele, Fiedorowicz, Jess G, Solmi, Marco , Berk, Michael , Solmi, Marco , Berk, Michael , Serretti, Alessandro , Prisco, Michele De , Oliva, Vincenzo , Fornaro, Michele , Dragioti, Elena , Yatham, Lakshmi N. , Keramatian, Kamyar , Shorr, Risa , Frye, Mark A. , Singh, Balwinder , Fanelli, Giuseppe , Gomes, Fabiano A., Nielsen, René Ernst , Fusar‐Poli, Paolo , Paribello, Pasquale , Manchia, Mirko , Bahji, Anees , Vázquez, Gustavo Héctor , Siafis, Spyridon , Leucht, Stefan , Delorme, Richard , Vieta, Eduard , Correll, Christoph Ulrich , Moher, David , Cortese, Samuele , Fiedorowicz, Jess G. , Raduà, Joaquim , Gosling, Corentin J.

Mayo Clinic

BMJ | August 11, 2026 | Volume: 394 | Issue: No issue available | Pages: e100216

10.1136/bmj-2026-100216 | PMID 42580772 Get It

Abstract Objectives To systematically evaluate the certainty of evidence for treatment strategies across age groups and mood phases in bipolar disorder, and develop an open access web platform to facilitate shared decision making. Design Living umbrella review, evaluation, analysis, and communication hub (U-REACH) project. Data sources PubMed, PsycInfo, and Cochrane library databases, from inception to 19 November 2024. Eligibility criteria for selecting studies Systematic reviews with network or pairwise meta-analyses of randomised controlled trials of pharmacological, nutraceutical, psychosocial, brain stimulation, or circadian rhythm based treatments, administered as monotherapy (without concurrent interventions), augmentation treatment (interventions added to an ongoing treatment regimen), or combination treatment (simultaneous initiation of two different interventions), examining any age group, bipolar disorder phase (ie, acute bipolar depression, mania or mixed episodes, or maintenance), treatment, control, or outcome. Results 77 studies met the inclusion criteria (21 network meta-analyses and 56 pairwise meta-analyses), including 116 unique pharmacological (n=74), brain stimulation (n=18), nutraceutical (n=13), psychosocial (n=8), and circadian rhythm based (n=3) treatments as monotherapy, augmentation, or combination therapy, along with five control interventions. These studies covered 133 unique outcomes (45 efficacy outcomes and 88 safety outcomes) resulting in 2510 meta-analyses with Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) ratings of the certainty of the evidence as high (n=236), moderate (n=827), low (n=986), and very low (n=461). A communication hub, the Evidence Based Interventions for Bipolar Disorder (EBI-BD) platform, was developed and the full results are freely available ( https://ebibd-database.org ), including the preference based tool (12 interventions and 17 safety outcomes). Interventions effective across outcomes varied by phases. For bipolar depression, effective interventions in adults were cariprazine, divalproex or valproate, fluoxetine, ketamine (augmentation), lamotrigine, lumateperone, lurasidone, olanzapine, olanzapine with fluoxetine, and quetiapine, whereas effective interventions in children and adolescents were lurasidone and olanzapine with fluoxetine. For mania episodes, effective interventions in adults were aripiprazole, asenapine, carbamazepine, cariprazine, divalproex or valproate, haloperidol, lithium, olanzapine, paliperidone, quetiapine (also augmentation), risperidone (also as augmentation), tamoxifen, and ziprasidone, whereas effective interventions in children and adolescents were aripiprazole, asenapine, olanzapine, quetiapine, and risperidone. For maintenance, interventions effective across outcomes in adults were aripiprazole (also the long acting injectable formulation), asenapine, divalproex or valproate, lithium, olanzapine, group psychoeducation (augmentation), quetiapine, and risperidone long acting injectable formulation. Interventions effective across phases were aripiprazole (also as augmentation and as a long acting injectable formulation), asenapine, cariprazine, cognitive behavioural therapy (augmentation), divalproex or valproate, lamotrigine, lithium, olanzapine (also as augmentation), paliperidone, quetiapine (also as augmentation), and risperidone (also as augmentation and the long acting injectable formulation) (adults). Treatment effects by neuroscience based nomenclature classes are also reported. Conclusions The EBI-BD tool can help clinicians make evidence based, personalised treatment decisions for bipolar disorder. This resource can inform clinical guidelines and provides a foundation for continuously improving bipolar disorder care as new evidence emerges. Trial registration Open Science Framework https://osf.io/pjmvn/ Readers’ note This is a living systematic review and may be updated in the next two years if additional evidence emerges.
Telemedicine Critical Care Billing For Hospitalized Medicare Fee-For-Service Beneficiaries, 2018–2024
Graves, Jonah M., Waken, R. J., Drewry, Anne M., Subramanian, Sanjay , Scott, Benjamin, Udeh, Chiedozie, Herasevich, Vitaly, Maddox, Karen E. Joynt , Joynt Maddox, Karen E , Ofoma, Uchenna R. , Graves, Jonah M. , Waken, R. J. , Drewry, Anne M. , Udeh, Chiedozie Ifeanyi , Herasevich, Vitaly

Mayo Clinic

Critical Care Medicine | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ccm.0000000000007301 | PMID 42565664 Get It

Objectives: Expanded coverage for telehealth during the COVID-19 pandemic allowed providers to bill for telemedicine services that were previously not reimbursable, including telemedicine critical care (TCC) services for critically ill patients. We aimed to characterize TCC billing practices among Medicare beneficiaries before, during, and after the COVID-19 pandemic. Design, Setting, and Patients: This was a serial cross-sectional study of adult Medicare Fee-For-Service beneficiaries with at least one bill for critical care at acute care hospitals from January 2018 to September 2024. TCC billing was identified using provider billing codes; multivariate regression models were used to determine characteristics associated with receipt of TCC. Key outcomes were patient-, provider-, and hospital-level characteristics associated with TCC billing. Interventions: None. Measurements and Main Results: Billing for TCC increased from 0.002% of critical care bills pre-pandemic to 0.01% of critical care bills during and after the pandemic. Patients billed for TCC were disproportionately likely to have COVID-19 but were otherwise relatively similar to critically ill patients not billed for TCC. Internal medicine/critical care providers accounted for the highest proportion of pandemic TCC bills (46.0%). TCC billing occurred more often at minor teaching hospitals (adjusted odds ratio [aOR], 1.21; 95% CI, 1.03–1.43) and at safety-net hospitals (aOR, 1.33; 95% CI, 1.04–1.70). TCC billing was less likely at small-sized hospitals (aOR, 0.39; 95% CI 0.26–0.58) and medium-sized hospitals (aOR, 0.67; 95% CI, 0.47–0.95), government-owned hospitals (aOR, 0.70; 95% CI, 0.57–0.86), for-profit hospitals (aOR, 0.58; 95% CI, 0.48–0.71), rural hospitals (aOR, 0.70; 95% CI, 0.55–0.89), and critical access hospitals (aOR, 0.59; 95% CI, 0.47–0.73). Conclusions: Billing for TCC among hospitalized critically ill Medicare beneficiaries increased during the pandemic but remained low as a proportion of all critical care bills. There was variability in utilization across subspecialties and lesser utilization at rural and critical access hospitals. Further studies are needed to characterize the clinical and economic consequences of this shift.
SADA-12 MALNUTRITION AS THE CANARY IN THE COAL MINE: NUTRITIONAL STATUS AND ITS ASSOCIATION WITH SURVIVAL IN PATIENTS WITH METASTATIC SPINE DISEASE
Versteeg, Anne L, Charest-Morin, Raphaële , Ramos, Rafael De La Garza, Laufer, I., Teixeira, William G J, Gassbarrini, Alessandro, Fehlings, Michael , Chou, Dean , Gokaslan, Ziya L, Netzer, Cordula, Luzzati, Alessandro, Verlaan, Jorrit-Jan, Goldshlager, Tony, Shin, John, O’Toole, John E, Sciubba, Daniel M. , Bettegowda, Chetan, Weber, Michael H, Mesfin, Addisu, Kawahara, Norio , Patel, Shalin S, Disch, Alexander C. , Reynolds, J., Dea, Nicholas, Sahgal, Arjun, Rhines, Laurence, Fisher, Charles G, Tumor, AO Spine Knowledge Forum, Goodwin, C Rory, Johnson, Eli , Versteeg, Anne , Ramos, Rafael De la Garza , Laufer, Ilya , Teixeira, William Gemio Jacobsen , Barzilai, Ori , Gasbarrini, Alessandro , Luzzati, Alessandro , Verlaan, Jorrit‐Jan , Goldschlager, Tony , Shin, John, Bettegowda, Chetan , Clarke, Michelle J. , Mesfin, Addisu , Reynolds, Jeremy , Lazáry, Áron , Boriani, Stefano , Dea, Nicolas , Rhines, Laurence D. , Fisher, Charles

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.110 Get It

Abstract Introduction Patients with metastatic spine disease (MSD) present with varying degrees of systemic illness and frailty. Given the palliative intent of surgery and radiation treatment for MSD, treatment risks must be judiciously weighed against potential benefits. We sought to examine the impact of peroperative nutritional status as measured by the PG-SGA on survival in patients undergoing surgery and radiation for MSD. Methods This study involved an international, multicenter prospective, observational registry of patients with MSD: AO Knowledge Forum Tumor’s Metastatic Tumor Research and Outcomes Network (MTRON). Variables including baseline demographics, oncologic data, adverse events (medical adverse events and surgical complications), length of stay, and nutritional status were prospectively collected. The Patient-Generated Subjective Global Assessment (PG-SGA) was used to evaluate nutritional status. Results A total of 589 patients were included in this study; 469 (80%) of whom underwent surgery and radiation and 120 (20%) of whom underwent radiation alone. The majority of patients (362, 61%) were classified as well nourished, however, 68 patients (12%) were classified as severely malnourished. Among patients that underwent surgery and radiation, the median overall survival of well nourished patients was 491 days compared to 117 days in the severely malnourished patients (p < 0.001). A multivariate analysis demonstrated severe malnourishment and ECOG performance status of 3 or 4 were associated with worse overall survival. Conclusion Malnutrition as measured by the PG-SGA demonstrated to be significantly and independently associated with perioperative survival in patients with MSD. Further studies that investigate optimal pre-treatment optimization for patients with MSD in order to mitigate morbidity and mortality risk are essential.
Prolonged postoperative dysphagia reduces return to work and physical activity after cervical spine surgery
Kussow, Nathan J. , Tippins, Nicholas P., Foreit, Anne M., Milne, Catherine, Narayanan, A., Neely, Matthew R., Reasoner, Jake T., Hannon, Kathleen M., Rezner, Aidan C., Alentado, Vincent J., Bisson, Erica F., Porche, Ken, Foley, Kevin T., Potts, Eric A., Milne, Catherine M., Alentado, Vincent J. , Bisson, Erica F. , Porche, Ken, Foley, Kevin T. , Potts, Eric A.

Mayo Clinic

Journal of Neurosurgery: Spine | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2026.3.spine251536 | PMID 42566788 Get It

OBJECTIVE Dysphagia has been shown to have an adverse effect on patient quality of life following cervical spine surgery, but its impact on patients’ ability to return to work (RTW) and return to physical activities (RTA) has never been investigated. This study aimed to evaluate the impact of postoperative dysphagia on patients’ ability to RTW and RTA after surgery. METHODS A prospectively maintained multi-institutional spine registry of patients who underwent cervical spine surgery between 2016 and 2023 was retrospectively reviewed. An Eating Assessment Tool-10 (EAT-10) score ≥ 3 was used to quantify preoperative and 12-month postoperative dysphagia. Prolonged dysphagia was defined as new dysphagia present at 12 months among patients without baseline dysphagia. RTW and RTA were assessed at baseline and 12 months postoperatively. Mixed-effects logistic regressions were used to evaluate the effect of dysphagia on RTW and RTA. RESULTS Of the 1208 patients meeting inclusion criteria, 240 (20%) experienced prolonged dysphagia, of whom 208 (87%) underwent anterior surgery. Preoperatively, 709 (59%) patients were fully employed or on short-term leave, 307 (25%) were retired, and 191 (16%) were otherwise unemployed. At the 12-month follow-up, RTW and RTA status were collected for 629 (95%) of the 664 employed patients who planned to RTW after surgery and 1127 (93%) of the total cohort, respectively. Significantly lower rates of RTW (86% vs 96%, p < 0.001) and RTA (62% vs 79%, p < 0.001) were observed in patients with prolonged dysphagia. Multivariable analysis identified dysphagia as being independently associated with lower odds of RTW (OR 0.35, 95% CI 0.14–0.86; p = 0.022) and RTA (OR 0.44, 95% CI 0.31–0.63; p < 0.001). CONCLUSIONS Prolonged postoperative dysphagia—defined as a new EAT-10 score ≥ 3 at 12 months—was associated with substantially lower odds of returning to work and physical activities after cervical spine surgery, underscoring the importance of dysphagia prevention and management in postoperative care.
Continuous Glucose Monitoring in Type 2 Diabetes and Beyond
Dower, Justin A. , Johansson, Minna , Camp, Anne, Lipska, Kasia J., Montori, Víctor M. , Lipska, Kasia J.

Mayo Clinic

JAMA Internal Medicine | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamainternmed.2026.2772 | PMID 42545686 Get It

Importance Continuous glucose monitoring (CGM), initially recommended primarily for people with type 1 diabetes, has rapidly expanded to patients with type 2 diabetes and, more recently, even to individuals without diabetes. This broadening use underscores the importance of critically examining the evidence supporting CGM across populations, clarifying where benefits are established, where they are modest, and where they remain uncertain. Observations We reviewed systematic reviews and meta-analyses of randomized trials and clinical guidelines evaluating CGM use beyond type 1 diabetes, with particular attention to glycemic outcomes, hypoglycemia, patient-reported outcomes, and potential unintended consequences in nonpregnant adults. In adults with type 2 diabetes, evidence from randomized trials consistently demonstrated that CGM use was associated, on average, with a modest yet consistent reduction in hemoglobin A 1c of approximately 0.3% compared with finger-stick monitoring or usual care; some patients benefited considerably more. Only limited and indirect evidence supported the adoption of CGM in people with type 2 diabetes not receiving glucose-lowering therapy or in those with prediabetes or obesity. Conclusions and Relevance CGM should be deployed in response to a specific patient problem rather than as a default intervention. Deliberate, equitable deployment of CGM that is aligned with patient goals, clinical context, and system capacity will be necessary to ensure that those most likely to benefit are not left behind, while avoiding overuse in populations for whom benefit remains unproven.
Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas
Mondello, Patrizia , Sadekova, Alisa , fede, ksenia, Dasari, Surendra , Au, Wesley , Kriukov, Kirill , Meerson, Mark, Novak, Joseph, Yang, Zhi-Zhang , Gysbers, Brianna J. , Villasboas, Jose, Wiebe, Daniil S. , Shvyrkova, Anastasiia, Margaryan, Sargis, Nesmelov, Alexander, Sarachakov, Aleksander, Petrosyants, Arman, Bagaev, Alexander , Novak, Anne J. , Casulo, Carla, Hsi, Eric, Fowler, Nathan, King, Rebecca, Singh, Harinder, Armand, Philippe, Pasqualucci, Laura, Ansell, Stephen M. , Binder, Moritz , Yang, Zhi-Zhang , Gysbers, Brianna J , Postovalova, Ekaterina , Wiebe, Daniil , Kotlov, Nikita , Wang, Yucai , Novak, Anne J , Habermann, Thomas , Maurer, Matthew , Cerhan, James R , Shlomchik, Mark , Ansell, Stephen M , Mondello, Patrizia , Dasari, Surendra , Au, Wesley, Binder, Moritz , Meerson, Mark , Novak, Joseph P. , Villasboas, José C. , Guzman, Emmanuel Contreras , Nesmelov, Alexander, Wang, Yucai , Habermann, Thomas M. , Hsi, Eric D. , Maurer, Matthew J. , Cerhan, James R. , Singh, Harinder, Armand, P., Pasqualucci, Laura , Burack, Richard

Mayo Clinic

No container title available | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10435263/v1 | PMID 42620132 Get It

Abstract Germinal center (GC)-derived lymphomas arise within a specialized immune ecosystem, yet whether malignant cells direct its remodeling remains unclear. Integrating genomic, transcriptomic, spatial, and functional analyses across follicular lymphoma and diffuse large B-cell lymphoma, we define a developmental framework linking malignant B-cell differentiation state to tumor microenvironment (TME) organization. Rather than segregating by histology, lymphomas align along a shared differentiation continuum in which proliferative dark zone (DZ) states associate with immune-depleted TMEs, whereas post-GC/memory B-cell (MBC) states drive inflamed but immunosuppressed TMEs. Spatial profiling reveals collapse of GC architecture and emergence of suppressive myeloid niches along this trajectory. Single-cell lineage reconstruction uncovers a DZ-to-MBC developmental axis underlying lymphoma evolution. Genetic reprogramming in vivo demonstrates that malignant differentiation state is sufficient to instruct TME remodeling. Collectively, these findings establish malignant differentiation state as a causal determinant of immune architecture across GC-derived lymphomas and identify lineage-directed immune reprogramming as a potential therapeutic strategy.
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer
Isaacs, Claudine, Nanda, Rita, Yau, C, Chien, A. Jo, Hershman, Dawn L., Stringer-Reasor, Erica M., Wallace, Anne M., Clark, Amy S., Kennedy, Laura C., Sanford, Amy, Boughey, JC , Albain, Kathy S. , Pusztai, Lajos, Kalinsky, Kevin M., Beckwith, Heather, Williams, Nicole O., Han, Hyo S., Falkson, Carla, Arora, Mili, Pohlmann, Paula R., Rozenblit, Mariya, Marshall, Natalie, Chen, Yunn-Yi, McGuinness, Julia E., Howard, Frederick M., Chen, Nan, Khoury, Katia, Lancaster, Rachael, Douglas, Emily, Wei, Mei, Mainor, Candace, LeStage, Barbara, Matthews, Jeffrey B. , Perlmutter, J, Symmans, W. Fraser, Yee, Douglas, Hylton, Nola M., Veer, Laura van ‘t , Rugo, Hope S., Berry, Donald A., Esserman, Laura J., Isaacs, Claudine , Yau, Christina , Chien, A. Jo , Hershman, Dawn L. , Stringer-Reasor, Erica , Thomas, Alexandra , Vaklavas, Christos , Clark, Amy S. , Kennedy, Laura Carpin , Pusztai, Lajos , Kalinsky, Kevin M. , Beckwith, Heather , Han, Hyo S , Falkson, Carla I. , Arora, Mili, Elias, Anthony , Pohlmann, Paula R. , Rozenblit, Mariya , Trivedi, Meghna S. , McGuinness, Julia Elizabeth , Howard, F , Khoury, Katia , Yeung, Kay T. , Douglas, Emily, Mainor, Candace , LeStage, Barbara , Delson, Amy , Asare, Adam L. , Swigart, Lamorna Brown , Hirst, Gillian L. , Symmans, W. Fraser , Yee, Douglas , Veer, Laura J. van’t , Rugo, Hope S. , DeMichele, Angela , Berry, Donald A., Esserman, Laura J.

Mayo Clinic

JAMA Oncology | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.2576 | PMID 42530945 Get It

Importance Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. Objective To evaluate the combination of anti−programmed cell death 1 protein (PD-1) cemiplimab and anti−lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2 -negative early-stage, high-risk breast cancer. Design, Setting, and Participants The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing randomized clinical platform trial being conducted at multiple US clinical sites including patients with early-stage (II or III) ERBB2 -negative, high-risk breast cancer. Participants, continuously enrolled since 2010, were adaptively randomized from February 2, 2020, to December 9, 2021, to one of several experimental neoadjuvant therapies or control groups based on receptor subtypes defined by hormone receptor (HR), ERBB2 status, and MammaPrint (Agendia Inc) molecular risk, categorized as high (MP1) or ultrahigh (MP2). Data were analyzed from January 1, 2022, to August 5, 2025. Interventions Both groups received weekly paclitaxel for 12 weeks, then doxorubicin and cyclophosphamide followed by surgery; concomitant with paclitaxel, the intervention group also received 4 doses of cemiplimab and fianlimab (PCF) every 3 weeks. Main Outcomes and Measures Pathologic complete response (pCR). Treatments graduated when they achieved 85% bayesian probability of success in a subtype-specific phase 3 trial. Pathway-specific biomarkers were assessed for response prediction. Results A total of 78 participants (mean [SD] age, 47 [39-54] years) were randomized to the intervention group, with 350 participants (mean [SD] age, 48 [39-57] years) randomized to the historical control population. PCF graduated in all clinical signatures, with pCR rates vs control of 44% (95% CI, 34%-53%) vs 21% (95% CI, 17%-25%) in all ERBB2 , 53% (95% CI, 39%-67%) vs 29% (95% CI, 22%-36%) in triple-negative, and 36% (95% CI, 23%-49%) vs 14% (95% CI, 9%-19%) in HR-positive and ERBB2 -negative disease. Among the total participants, 16 (21%) experienced adrenal insufficiency, including hypophysitis (11% grade 3 or 4), mostly occurring after immunotherapy completion. PCF was found to be highly effective in the subset of patients with immune signature positive status (ImPrint positive). Conclusions and Relevance In this randomized clinical trial, the combination of PD-1 and anti−LAG-3 inhibition with standard NAC was effective in early-stage ERBB2 -negative breast cancer, particularly in patients displaying a positive ImPrint immune signature. These results warrant further definitive trials. Trial Registration ClinicalTrials.gov Identifier: NCT01042379
Recovery rates of postoperative dysphagia following cervical spine surgery
Neely, Matthew R., Tippins, Nicholas P., Foreit, Anne M., Alentado, Vincent J., Milne, Catherine, Kussow, Nathan J. , Narayanan, A., Rezner, Aidan C., Hannon, Kathleen M., Ef, Bisson, Porche, Ken, Foley, Kevin T., Potts, Eric A., Alentado, Vincent J. , Milne, Catherine M., Bisson, Erica F. , Porche, Ken, Foley, Kevin T. , Potts, Eric A.

Mayo Clinic

Journal of Neurosurgery: Spine | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2026.2.spine251597 | PMID 42537229 Get It

OBJECTIVE This study examines the recovery rates of patients who experience postoperative dysphagia within 1 month following cervical spine surgery. METHODS Data from a prospectively maintained multi-institutional quality registry were retrospectively analyzed. Eating Assessment Tool-10 (EAT-10) questionnaire scores were collected at baseline and 1, 3, and 12 months postoperatively, with total scores ≥ 3 indicating dysphagia. Patients were grouped by whether they reported baseline dysphagia to assess the impact of baseline dysphagia on recovery. Recovery was defined as resolution of postoperative dysphagia and not reporting the condition at any follow-up time point. Patients were excluded from the recovery model if they did not report dysphagia within 1 month of surgery. Recovery to baseline was defined as reporting a postoperative EAT-10 score equal to or less than the baseline score at subsequent time points. Patients were excluded from the recovery-to-baseline model if they did not report EAT-10 scores within 1 month of surgery that were worse than their baseline score. Survival curves were generated for both models. RESULTS Of the 2003 patients in the registry, 627 met inclusion criteria for the recovery curve and 714 for the recovery-to-baseline curve. Of the patients without baseline dysphagia, 498 developed new postoperative dysphagia within 1 month, with cumulative recovery probabilities of 39.5% by 3 months and 59.1% by 12 months after cervical spine surgery. Furthermore, of the patients without baseline dysphagia, 73.5% (175/238) who reported no dysphagia at 3 months and 32.5% (68/209) who reported no dysphagia at 12 months experienced long-term recovery. Eighty patients with baseline dysphagia reported worse EAT-10 scores within 1 month, with cumulative probabilities of improvement to baseline or below of 37.7% by 3 months and 54.1% by 12 months. Patients with baseline dysphagia were significantly less likely to recover than patients without baseline dysphagia (hazard ratio [HR] 0.37, 95% CI 0.26–0.53; p < 0.001) but significantly more likely to recover to baseline (HR 1.45, 95% CI 1.05–2.00; p = 0.025). CONCLUSIONS Patients who develop postoperative dysphagia within 1 month of cervical spine surgery generally see symptomatic improvement over time. This analysis may aid in clinical decision-making when informing patients about the risk of developing postoperative dysphagia and the recovery rate of this surgical complication.
Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world
Snyder, Heather M. , Tampi, Malavika P. , Aisen, Paul S., Allegri, Ricardo, Apostolova, Liana G., Atri, Alireza, Aurora, Sheena, Caramelli, Paulo, Cummings, Jeffrey, Fox, Nick C., Hardy, John, Lamb, Bruce T., Levey, Allan, Lopez, Oscar, Mummery, Catherine, Nitrini, Ricardo, Pahlke, Sarah, Petersen, Ronald C., Pike, K. Joanne, Porsteinsson, Anton P., Rabinovici, Gil D., Rafii, Michael, Raman, Rema, Sabbagh, Marwan N., Salloway, Stephen P., Scheltens, Philip, Schott, Jonathan M., Selkoe, Dennis J., Sevlever, Gustavo, Sperling, Reisa, Tansey, Malu Gamez, Dyck, Christopher van, Zetterberg, Henrik, Carrillo, Maria C., Hardy, John , Grinberg, Lea Tenenholz, Hardy, John , Aisen, Paul , Allegri, Ricardo , Apostolova, Liana G. , Atri, Alireza , Caramelli, Paulo , Crivelli, Lucía , Cummings, Jeffrey L. , Strooper, Bart De , Fox, Nick C, Grinberg, Lea T. , Lamb, Bruce T. , López, Oscar L. , Mummery, Catherine J. , Nitríni, Ricardo , Pahlke, Sarah , Petersen, Ronald C. , Porsteinsson, Anton P. , Rabinovici, Gil D. , Rafii, Michael S. , Raman, Rema, Salloway, Stephen , Scheltens, Philip , Schott, Jonathan M. , Selkoe, Dennis J. , Sevlever, Gustavo Emilio , Sperling, Reisa Anne , Tansey, Malú G. , Dyck, Christopher H. van , Zetterberg, Henrik , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | July 28, 2026 | Volume: 22 | Issue: 7 | Pages: No page available

10.1002/alz.71696 | PMID 42516031 Get It

Abstract In response to a Cochrane review (published in April 2026) on the clinical trials of monoclonal antibodies targeting beta amyloid, this perspective outlines a number of critiques. The scientists, methodologists, subject‐matter experts, and clinicians on this perspective strongly recommend that the Cochrane editorial board consider a call for editorial response, correction of press materials, or commissioned reply to this review for four overarching reasons: (1) decision to pool antibodies that do and do not clear beta amyloid, (2) decision to include studies from a time when biomarkers of Alzheimer's disease were not available, (3) analytical and methodological limitations of the approach used, (4) conflating the distinct roles and methodological processes of systematic review and guideline methodologies, (5) contextualizing the present critique within the existing evidence‐synthesis literature, and (6) mechanistic inference beyond the scope of the presented analyses. Conclusions that may not accurately reflect treatment‐specific effects could cause significant downstream clinical and psychosocial harm to those currently undergoing treatment and their family members as well as individuals considering participation in Alzheimer's clinical trials.